Can PureTech Health turn things round?
Independent analyst Alistair Strang investigates this small-cap biotech firm's share price which is currently respecting an historical downtrend.
8th September 2026 07:26
by Alistair Strang from Trends and Targets
PureTech Health (LSE:PRTC) represent a fairly apt focus for discussion, following a flurry of visits to our local GP’s in-house vampire, a lovely lady called Fiona who regards it as her life work to extract blood from the innocent.
- Invest with ii:Open a Stocks & Shares ISA | Top ISA Funds | Transfer your ISA to ii
PureTech claims to have an orally administered weight-loss solution. In our book, any initiative which does not involve injections deserves extremely positive attention.
The company boasts a share price which has been waffling around since breaking the closing price downtrend from 2021, the price carefully respecting this historical downtrend and building hope for the future. Perhaps their half-year results announcement on 22 September is supposed to cause a sharp surge upward.
If we’re right – and we expect to be – above just 129p should mean reaching an initial 133p with our secondary, if bettered, at a comfortable 140.5p. This secondary target level is liable to prove important, launching the share price into a zone where a long-term third level ambition of 162p makes some sense. Visually, this is our expectation.
Should things decide to go wrong, below 113p should apparently trigger reversals to an initial 109p with our secondary, if broken, at 102p. And perhaps a solid bounce.
Source: Trends and Targets. Past performance is not a guide to future performance.
Alistair Strang has led high-profile and "top secret" software projects since the late 1970s and won the original John Logie Baird Award for inventors and innovators. After the financial crash, he wanted to know "how it worked" with a view to mimicking existing trading formulas and predicting what was coming next. His results speak for themselves as he continually refines the methodology.
Alistair Strang is a freelance contributor and not a direct employee of Interactive Investor. All correspondence is with Alistair Strang, who for these purposes is deemed a third-party supplier. Buying, selling and investing in shares is not without risk. Market and company movement will affect your performance and you may get back less than you invest. Neither Alistair Strang or Interactive Investor will be responsible for any losses that may be incurred as a result of following a trading idea.
These articles are provided for information purposes only. Occasionally, an opinion about whether to buy or sell a specific investment may be provided by third parties. The content is not intended to be a personal recommendation to buy or sell any financial instrument or product, or to adopt any investment strategy as it is not provided based on an assessment of your investing knowledge and experience, your financial situation or your investment objectives. The value of your investments, and the income derived from them, may go down as well as up. You may not get back all the money that you invest. The investments referred to in this article may not be suitable for all investors, and if in doubt, an investor should seek advice from a qualified investment adviser.
Full performance can be found on the company or index summary page on the interactive investor website. Simply click on the company's or index name highlighted in the article.